The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $1.13.

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...